"Benzeneacetamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds based on benzeneacetamide, that are similar in structure to ACETANILIDES.
| Descriptor ID |
D044482
|
| MeSH Number(s) |
D02.065.064.294 D02.455.426.559.389.048
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzeneacetamides".
Below are MeSH descriptors whose meaning is more specific than "Benzeneacetamides".
This graph shows the total number of publications written about "Benzeneacetamides" by people in this website by year, and whether "Benzeneacetamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2017 | 2 | 0 | 2 |
| 2019 | 0 | 1 | 1 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzeneacetamides" by people in Profiles.
-
Safety and efficacy of nepafenac punctal plug delivery system in controlling postoperative ocular pain and inflammation after cataract surgery. J Cataract Refract Surg. 2021 Feb 01; 47(2):158-164.
-
Reply to comment on: Safety and efficacy of a nepafenac punctal plug delivery system in controlling postoperative ocular pain and inflammation after cataract surgery. J Cataract Refract Surg. 2021 01 01; 47(1):143-144.
-
Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma. Nat Commun. 2019 03 21; 10(1):1296.
-
Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells. Oncotarget. 2017 May 30; 8(22):35863-35876.
-
Pseudophakic cystoid macular edema prevention and risk factors; prospective study with adjunctive once daily topical nepafenac 0.3% versus placebo. BMC Ophthalmol. 2017 Feb 20; 17(1):16.
-
The kappa-opioid agonist, U-69593, decreases acute amphetamine-evoked behaviors and calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum. J Neurochem. 1999 Sep; 73(3):1066-74.
-
Kappa receptor activation attenuates L-trans-pyrrolidine-2,4-dicarboxylic acid-evoked glutamate levels in the striatum. J Neurochem. 1998 Feb; 70(2):626-34.